The specter of generic competition has consistently loomed around copyright’s famous drug, Viagra, triggering questions about the outlook of connected medicinal holdings. While first years saw significant returns, the exclusivity lapse has opened the door for less expensive alternatives, potentially diminishing earnings and creating a significant